Fludarabine: all 769 studies that test it

Page 5 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.

• Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesCompletedNCT00038857Phase 2Results posted
• Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibCompletedNCT00036738Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedNCT00006184Phase 2Results posted
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaCompletedNCT00003659Phase 2Results posted
• Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedNCT00001832Phase 2Results posted
• Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisCompletedNCT00001586Phase 2Results posted
• Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid LeukemiaActive, not recruitingNCT07232953Phase 2
• UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesActive, not recruitingNCT07155369Not applicable
• Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular CarcinomaSuspendedNCT06968195Phase 1
• UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT06698744Phase 1
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
• ALPP CAR-T Cells for ALPP-Positive Advanced Solid TumorsCompletedNCT06556108Phase 1/2
• Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory LymphomaStatus unknownNCT06532643Early Phase 1
• Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic CancerCompletedNCT06464965Phase 1
• Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaSuspendedNCT06447987Phase 1
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaCompletedNCT06151847Phase 2
• Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerWithdrawnNCT06094842Phase 1
• CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT05950113Phase 1
• Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerActive, not recruitingNCT05922930Phase 1/2
• CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingNCT05767359Phase 2
• CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionActive, not recruitingNCT05707273Phase 1
• A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)TerminatedNCT05600426Phase 3
• Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05577000Phase 1
• Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid TumorsWithdrawnNCT05531708Phase 1
• B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid TumorsStatus unknownNCT05515185Early Phase 1
• Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 1
• Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesWithdrawnNCT05201183Phase 1/2
• 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05139004Phase 1
• TriPRIL CAR T Cells in Multiple MyelomaActive, not recruitingNCT05020444Phase 1
• Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple MyelomaStatus unknownNCT05008536Early Phase 1
• Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)CompletedNCT04942730Phase 2
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
• GFRα4 CAR T Cells in MTC PatientsActive, not recruitingNCT04877613Phase 1
• A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
• A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
• Novel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaStatus unknownNCT04706936Phase 1
• Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHLActive, not recruitingNCT04697940Phase 1/2
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04696731Phase 1
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Active, not recruitingNCT04637763Phase 1
• CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04626765Early Phase 1
• CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04626752Early Phase 1
• CAR-T Cells in Treating Patients With Relapsed or Refractory NHLStatus unknownNCT04626739Early Phase 1
• Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04626726Early Phase 1
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedNCT04539366Phase 1
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain CancerWithdrawnNCT04521946Phase 1
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedNCT04425655Phase 2
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
• Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic MalignanciesStatus unknownNCT04264078Early Phase 1
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2
• Trial Testing Safety of IL-21 NK Cells for Induction of R/R AMLCompletedNCT04220684Phase 1
• A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingNCT04217278Phase 2/3
• CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT04214886Phase 1
• Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT04173988Early Phase 1
• Autologous Transplant Targeted Against Crohn'sWithdrawnNCT04154735Phase 2
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)WithdrawnNCT04093648Phase 1
• CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.Status unknownNCT04037566Phase 1
• Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04018937Phase 2
• a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
• Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid TumorsTerminatedNCT03992326Phase 1
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsActive, not recruitingNCT03967223Phase 2
• Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
• Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAAStatus unknownNCT03821987Not applicable
• The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerStatus unknownNCT03814447Early Phase 1
• MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerStatus unknownNCT03799913Early Phase 1
• Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03716856Phase 1
• CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaSuspendedNCT03710421Phase 1
• IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCTTerminatedNCT03696537Phase 1
• Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
• CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
• Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTerminatedNCT03448978Phase 1
• AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaActive, not recruitingNCT03434769Phase 1
• Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic OvarianStatus unknownNCT03412526Phase 2
• Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03380039Not applicable
• Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian CancerStatus unknownNCT03335241Phase 2
• A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWithdrawnNCT03324243Phase 2
• Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Not applicable
• Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03247088Phase 1/2
• Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03241940Phase 1
• Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorStatus unknownNCT03171831Phase 4
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialCompletedNCT03158935Phase 1
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT03126864Phase 1
• Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesActive, not recruitingNCT03121014Phase 2
• BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple MyelomaStatus unknownNCT03093168Phase 1

← Fludarabine overview